264TiP A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
| Autor: | Janjigian, Y.Y.1 (AUTHOR), Lloyd, C.2 (AUTHOR), de Giorgio-Miller, V.G.3 (AUTHOR), Chang, Y-T.4 (AUTHOR), Lee, J.5 (AUTHOR) |
|---|---|
| Zdroj: | Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1502-S1503. 2p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|